{"DataElement":{"publicId":"6454521","version":"1","preferredName":"Patient HIV Infectious Disorder Current Effective Antiretroviral Therapy With Undetectable Viral Load Trial Eligibility Criteria Indicator","preferredDefinition":"The coded indicator to determine clinical trial participation for questions related to HIV infection, current effective treatment with medication(s) that target the virus directly with undetectable viral load, as outlined in the study protocol.","longName":"HIV_EFF_ANTVRL_TX_UNDET_VL","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6454493","version":"1","preferredName":"Patient Human Immunodeficiency Virus Infectious Disorder Current Effective Antiretroviral Therapy With Undetectable Viral Load Clinical Trial Eligibility Criteria","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses._A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact._Occurring in or belonging to the present time._Existing in fact and ready for service._Treatment of retroviral infections with medications that target the virus directly, limiting the ability of infected cells to produce new virus particles._Used to indicate the presence of something or someone._The inability to be noticed, identified or discovered._The number of viral particles (usually HIV) in a sample of blood plasma._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233604v1.0:6454491v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6454491","version":"1","preferredName":"Human Immunodeficiency Virus Infectious Disorder Current Effective Antiretroviral Therapy With Undetectable Viral Load Clinical Trial Eligibility Criteria","preferredDefinition":"The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.:A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.:Occurring in or belonging to the present time.:Existing in fact and ready for service.:Treatment of retroviral infections with medications that target the virus directly, limiting the ability of infected cells to produce new virus particles.:Used to indicate the presence of something or someone.:The inability to be noticed, identified or discovered.:The number of viral particles (usually HIV) in a sample of blood plasma.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"6454491v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Immunodeficiency Virus","conceptCode":"C14219","definition":"The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Current","conceptCode":"C25471","definition":"Occurring in or belonging to the present time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Effective","conceptCode":"C49287","definition":"Existing in fact and ready for service.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Antiretroviral Therapy","conceptCode":"C94631","definition":"Treatment of retroviral infections with medications that target the virus directly, limiting the ability of infected cells to produce new virus particles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Undetectable","conceptCode":"C111568","definition":"The inability to be noticed, identified or discovered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Viral Load","conceptCode":"C51952","definition":"The number of viral particles (usually HIV) in a sample of blood plasma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"774476AE-A423-448A-E053-F662850ABE61","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"ONEDATA","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"774476AE-A434-448A-E053-F662850ABE61","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"TAYLORT","dateModified":"2018-11-01","changeDescription":"11/1/18 TMT released. 10-2-18 tmt/10200.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876422","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"CCTG","type":"USED_BY","context":"CCTG"},{"name":"IE_IEORRES_HIV","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient has human immunodeficiency virus (HIV) infection, are they on an effective anti-retroviral regimen utilizing agents that do not strongly induce or inhibit cytochrome P450 (CYP) 3A4, and has an undetectable viral load measured within 6 months prior to study registration?","url":null,"context":"Theradex"},{"name":"If patient is Human Immunodef","type":"Preferred Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"If patient is HIV positive, is the patient on a modern therapeutic regimen utilizing non-CYP-interactive agents, with an undectectable viral load, CD4 count greater than 350 cell/mm3, and no history of AIDS-defining opportunistic infections?","url":null,"context":"COG"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"If patient has human immunodeficiency virus (HIV) does patient have: undetectable HIV load by standard PCR clinical assay (within 60 days prior to registration), has absolute CD4 count greater than or equal to 200 mm3 within 60 days prior to registration, is willing to maintain adherence to combination antiretroviral therapy, has no history of AIDS defining condition (other than lymphoma or CD4 cell count less than 200 mm3), and is likely to have near normal lifespan if not for the presence of relapsed/refractory lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"If patient has a history of being   Human Immunodeficiency Virus (HIV) positive, are they stable on their anti-retroviral regimen, are healthy from an HIV perspective and has an undetectable HIV viral load?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If patient is infected with HIV, are they on an effective antiretroviral therapy with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral regimen utilizing non-CYP-interactive agents and has an undetectable viral load?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient is known to be human immunodeficiency virus (HIV) positive, are the following criteria met: CD4 count greater than 350 cells/mm3, Undetectable viral load, maintained on modern therapeutic regimens utilizing non-CYP-interactive agents (e.g., excluding ritonavir),  and has no history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"If patient is known to be human immunodeficiency virus (HIV) positive are the following criteria met: CD4 count greater than 350 cells/mm3, undetectable viral load, maintained on modern therapeutic regimens utilizing non-CYP-interactive agents and no history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Is patient know to be human immunodeficiency virus (HIV) positive are the following criteria met: CD4 count greater than 350 cells/mm3, Undetectable viral load, maintained on modern therapeutic regimens utilizing non-CYP-interactive agents (e.g., excluding ritonavir),  and has no history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is HIV-positive and on combination antiretroviral therapy, are they on effective antiretroviral therapy, have undetectable viral load within 6 months, and there is no drug-drug interaction with M6220?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient is HIV-infected, is patient on an anti-retroviral regimen with evidence of at least two undetectable viral loads within the past 6 months on this same regimen?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"If patient has a history of human immunodeficiency virus (HIV) infection, are they on an effective anti-retroviral regimen utilizing agents that do not strongly induce or inhibit cytochrome P450 (CYP) 3A4, and has an undetectable viral load measured within 6 months prior to study registration?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient is human immunodeficiency virus (HIV)-infected, are they on an effective antiretroviral regimen utilizing non-CYP-interacting agents, with an undetectable viral load, CD4 count is greater than 350 cells/mm3, and there is no history of Acquired Immune Deficiency Syndrome (AIDS)-defining opportunistic infections?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"If patient has known human immunodeficiency virus (HIV) are the following criteria met: they are on a stable regimen of highly active anti-retroviral therapy (HAART), there is no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infection, the CD4 count above 250 cells/mcL and they have undetectable HIV viral load on standard PCR-based testing?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient has human immunodeficiency virus (HIV) and receiving an effective anti-retroviral therapy, does patient have an undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"If patient is human immunodeficiency virus (HIV)-infected, is patient on an effective anti-retroviral therapy (with no medications prohibited by this protocol [e.g. drug-drug interactions]) and has undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy, that does not have the potential for drug-drug interactions as judged by the treating investigator, with undetectable viral load within 3 months?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient has human immunodeficiency virus (HIV) infection, are they on an effective anti-retroviral regimen utilizing agents that do not strongly induce or inhibit cytochrome P450 (CYP) 3A4, and has an undetectable viral load measure?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy with undetectable viral load within 6 months, values not conforming to this may be enrolled at the treating physician's discretion?","url":null,"context":"Theradex"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"If the patient is HIV-infected, is the patient on effective antiretroviral therapy with an undetectable viral load within 6 months of study enrollment?","url":null,"context":"PBTC"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV) positive are the following eligibility requirements met: they are stable on their anti-retroviral regimen, are healthy from an HIV perspective, and have an undetectable HIV viral load?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient is Human immunodeficiency virus (HIV) positive, is patient on effective anti-retroviral therapy with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy (provided there is no expected drug-drug interaction) with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient receiving effective antiretroviral therapy, with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"If patient is HIV-positive, is patient on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, and viral load is undetectable?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"If patient is Human immunodeficiency virus (HIV) infected, receiving an effective, stable regimen of anti-retroviral therapy (ART), is not receiving medications otherwise prohibited by this protocol [e.g. drug-drug interactions]) and has an undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"If patient has a history of HIV-positive on antiretroviral therapy, is viral load undetectable?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"If patient is HIV positive, are they on an effective anti-retroviral therapy with undetectable viral load within 6 months, CD4 count is greater than 250 cells/mcL, and is not receiving prophylactic therapy for an opportunistic infection?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient is positive for human immunodeficiency virus (HIV), does patient have the following: a stable regimen of highly active anti-retroviral therapy (HAART), no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections, a CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based test?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If patient is HIV positive, the following criteria must be met: patient does not have a history of Kaposi sarcoma and/or Multicentric Castleman Disease, on FF and have undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"If patient is enrolled in the HIV positive expansion cohort, is patient HIV infected and on retroviral therapy with an undetectable viral load within 6 months of enrollment?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"If patient was HIV-infected and on effective anti-retroviral therapy, was there undetectable viral load within 6 months prior to enrollment?","url":null,"context":"COG"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"If patient is infected with HIV, is patient on effective anti-retroviral therapy with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"If patient was HIV-infected and on effective anti-retroviral therapy, was there undetectable viral load within 6 months prior to enrollment?","url":null,"context":"COG"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV) positive are the following eligibility requirements met: they are stable on their anti-retroviral regimen, are healthy from an HIV perspective, have an undetectable HIV viral load and a CD4 count greater than or equal to 250 cells/µL within 7 days of enrollment, must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"If patient is HIV positive, the following criteria must be met: patient does not have a history of Kaposi sarcoma and/or Multicentric Castleman Disease, on effective anti-retroviral therapy, and have undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"If patient is HIV-infected, is patient on effective non-CYP3A4 interacting anti-retroviral therapy with undetectable viral load within 6 months of enrollment to this trial?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"If patient has HIV infection, have the following criteria been met: (a) they are on a stable regimen of highly active anti-retroviral therapy (HAART) with no medications otherwise prohibited by this protocol (e.g. drug-drug interactions,), e.g. medications cannot be CYP3A4 inducers or inhibitors and cannot interact with ZEN003694), and (b) they require no concurrent antibiotics or antifungals for the prevention of opportunistic infections, and (c) they have a CD4 count above 250 cell/mcL and an undetectable viral load on standard PCR-based tests within 1 month of initiation of study treatment?","url":null,"context":"Theradex"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Is the patient on effective anti-retroviral therapy with undetectable viral load within 6 months of study entry?","url":null,"context":"NRG"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy with undetectable viral load (CD4 count of greater than 250 cells/mcL) within 6 months and they are not receiving prophylactic therapy for an opportunistic infection?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"If patient is Human immunodeficiency virus (HIV)-infected and on effective anti-retroviral therapy, is viral load undetectable within past 28 days?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"If patient has a known history of HIV-infection, is patient on effective anti-retroviral therapy with undetectable viral load within 6 months of study enrollment?","url":null,"context":"Theradex"},{"name":"CCTG_01","type":"Alternate Question Text","description":"Patient with known Human Immunodeficiency Virus (HIV), taking effective anti-retroviral therapy and has an undetectable viral load within 6 months of enrollment.","url":null,"context":"CCTG"},{"name":"CRF text1","type":"Alternate Question Text","description":"Known HIV Positive on effective anti-retroviral therapy with undetectable viral load within 6 months of registration","url":null,"context":"Alliance"},{"name":"Alliance Question Text","type":"Alternate Question Text","description":"Known HIV positive?","url":null,"context":"Alliance"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"If patient is human immunodeficiency virus (HIV)-infected, patient is on effective anti-retroviral therapy with undetectable viral load within 6 months and the anti-retroviral therapy does not have the potential for drug-drug interactions as judged by the treating investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"If patient is infected with HIV, are they on an effective antiretroviral therapy with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy, that does not have the potential for drug-drug interactions as judged by the treating investigator, with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"If patient was HIV-infected and on effective antiretroviral therapy that does not interact with planned study agents, was there undetectable viral load within 6 months of treatment?","url":null,"context":"COG"},{"name":"COG CRF TEXT 5","type":"Alternate Question Text","description":"If patient is an HIV-infected patient on an effective anti-retroviral therapy with an undetectable viral load within 6 months, is the patient receiving strong anti-retroviral inhibitors or inducers of CYP3A4, CYP2D6, and/or MRP2 transporter protein?","url":null,"context":"COG"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"If the patient is known to be HIV-positive, are the following criteria met: CD4 count is greater than 350 cells/mm3; undetectable viral load for 6 months prior to enrollment and maintained on modern therapeutic regimens utilizing non-CYP-interactive agents?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"If patient is Human Immunodeficiency Virus (HIV)-infected, is patient on effective antiretroviral therapy (that is not excluded by protocol) with undetectable viral load within 6 months?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"If patient is Human immunodeficiency virus (HIV)-infected, is patient on effective combination antiretroviral therapy, HIV is well-controlled, viral load is undetectable within 6 months and an HIV viral load test was completed within 28 days prior to enrollment?","url":null,"context":"Theradex"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"If patient has a history of HIV, has patient been on effective anti-retroviral therapy with undetectable viral load and has a T-cell count above the lower limit of normal within 6 months of this trial?","url":null,"context":"COG"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77450A99-FD79-3165-E053-F662850A691D","latestVersionIndicator":"Yes","beginDate":"2018-10-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-10-02","modifiedBy":"KUMMEROA","dateModified":"2023-11-02","changeDescription":"11/1/18 TMT released. 10-2-18 tmt/10200.","administrativeNotes":"2023.11.2 AQT added per ticket request CADSR0003032. ak 2023.1.17 AQT added per ticket request CADSR0001913. ak 8/2/2022: fixed the box symbol in AQT_wz 6.21.2022: added AQT for Alliance per req#CADSR0001212.wz","unresolvedIssues":null,"deletedIndicator":"No"}}